{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Long-Acting+Beta+Agonist",
    "query": {
      "intervention": "Long-Acting Beta Agonist"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 56,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Long-Acting+Beta+Agonist&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T14:15:06.767Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01313650",
      "title": "A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "62.5/25mcg",
          "type": "DRUG"
        },
        {
          "name": "62.5mcg",
          "type": "DRUG"
        },
        {
          "name": "25mcg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1538,
      "start_date": "2011-03-01",
      "completion_date": "2012-04-05",
      "has_results": true,
      "last_update_posted_date": "2018-08-06",
      "last_synced_at": "2026-09-28T14:15:06.767Z",
      "location_count": 37,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Ormond Beach, Florida + 33 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01313650"
    },
    {
      "nct_id": "NCT00910689",
      "title": "Drug and Non-Drug Treatment Of Severe Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine Headache"
      ],
      "interventions": [
        {
          "name": "Propranolol or nadolol",
          "type": "DRUG"
        },
        {
          "name": "Placebo control",
          "type": "DRUG"
        },
        {
          "name": "Behavioral Migraine Management (BMM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Optimal Acute Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Ohio University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 232,
      "start_date": "2001-07",
      "completion_date": "2005-11",
      "has_results": true,
      "last_update_posted_date": "2016-11-22",
      "last_synced_at": "2026-09-28T14:15:06.767Z",
      "location_count": 2,
      "location_summary": "Athens, Ohio • Westerville, Ohio",
      "locations": [
        {
          "city": "Athens",
          "state": "Ohio"
        },
        {
          "city": "Westerville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910689"
    },
    {
      "nct_id": "NCT01712854",
      "title": "Effects of Symbicort on the Ventilatory Kinematics",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Obstructive Lung Disease"
      ],
      "interventions": [
        {
          "name": "Budesonide",
          "type": "DRUG"
        },
        {
          "name": "Symbicort",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2012-03",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2016-09-02",
      "last_synced_at": "2026-09-28T14:15:06.767Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712854"
    },
    {
      "nct_id": "NCT01316900",
      "title": "24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "GSK573719/GW642444 125/25",
          "type": "DRUG"
        },
        {
          "name": "GSK573719/GW642444 62.5/25",
          "type": "DRUG"
        },
        {
          "name": "GW642444",
          "type": "DRUG"
        },
        {
          "name": "tiotropium bromide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 846,
      "start_date": "2011-03-01",
      "completion_date": "2012-04-24",
      "has_results": true,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-09-28T14:15:06.767Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • San Diego, California • DeLand, Florida + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01316900"
    },
    {
      "nct_id": "NCT05935332",
      "title": "Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "RPT193",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "RAPT Therapeutics, Inc., a member of the GSK plc group of companies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 38,
      "start_date": "2023-07-05",
      "completion_date": "2024-06-21",
      "has_results": true,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-09-28T14:15:06.767Z",
      "location_count": 13,
      "location_summary": "San Jose, California • Stockton, California • Westminster, California + 9 more",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05935332"
    },
    {
      "nct_id": "NCT01777334",
      "title": "The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Umeclidinium/Vilanterol 62.5/25 mcg",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium 18 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 905,
      "start_date": "2013-01-23",
      "completion_date": "2013-09-24",
      "has_results": true,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-09-28T14:15:06.767Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Riverside, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Panama City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01777334"
    },
    {
      "nct_id": "NCT01124422",
      "title": "Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "fluticasone propionate/salmeterol inhalation powder DISKUS 250/50",
          "type": "DRUG"
        },
        {
          "name": "tiotropium bromide inhalation powder HandiHaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 255,
      "start_date": "2010-07-19",
      "completion_date": "2011-05-02",
      "has_results": true,
      "last_update_posted_date": "2017-11-08",
      "last_synced_at": "2026-09-28T14:15:06.767Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01124422"
    },
    {
      "nct_id": "NCT01017952",
      "title": "A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF/GW642444 Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "GW642444 Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1635,
      "start_date": "2009-09-25",
      "completion_date": "2011-10-17",
      "has_results": true,
      "last_update_posted_date": "2018-08-31",
      "last_synced_at": "2026-09-28T14:15:06.767Z",
      "location_count": 89,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 79 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Tallassee",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01017952"
    },
    {
      "nct_id": "NCT01355991",
      "title": "Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Spinal Cord Injury"
      ],
      "interventions": [
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James J. Peters Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2011-08",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2015-10-23",
      "last_synced_at": "2026-09-28T14:15:06.767Z",
      "location_count": 2,
      "location_summary": "West Orange, New Jersey • The Bronx, New York",
      "locations": [
        {
          "city": "West Orange",
          "state": "New Jersey"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01355991"
    },
    {
      "nct_id": "NCT01336608",
      "title": "A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/Vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 446,
      "start_date": "2011-03-04",
      "completion_date": "2014-11-04",
      "has_results": true,
      "last_update_posted_date": "2017-11-08",
      "last_synced_at": "2026-09-28T14:15:06.767Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336608"
    }
  ]
}